Patients with lung cancer who have a certain gene mutation are more likely to respond to the chemotherapeutic agents cisplatin or carboplatin, according to research conducted at the Massachusetts General Hospital.

Results of this retrospective study may help oncologists better select patients for these commonly prescribed drugs. “We hope that this type of research will one day enable doctors and patients to make more informed decisions about chemotherapy treatments,” study author Sarada Gurubhagavatula said in a statement.